Prof Brigette Dréno speaks with ecancer at the EADO 2018 congress in Barcelona about the different therapies for targeting brain metastases.
Prof Dréno explains that the combination therapy of anti PD-1 and ipilimumab immunotherapy is the best treatment for brain metastases.
He explains that for patients with a metastatic disease such as isolated systemic metastasis similar results or better can be achieved through surgery.
She acknowledges the toxicity of this therapy but that it is often only an initial reaction and that severe adverse events could be linked to a clinical response.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.